论文部分内容阅读
作者用纯化的Vero细胞狂犬病疫苗(PVRV)按泰国红十字会皮内接种(TRC-ID)程序进行接触后预防,以评价该方案的效果。按下列标准选择100例患者,(1)经荧光抗体试验证实为狂犬病动物咬伤;(2)咬伤至开始治疗的时间不超过48小时;(3)因皮肤损伤导致出血;(4)患者未用皮质类固醇或免疫抑制剂,非酒精或药物成瘾者,无慢性肝病;(5)以前未接种过狂犬病疫苗。每0.5ml疫苗含抗原3.17IU。所有患者均于第0、3和7天在两侧三角肌区皮内注射0.1ml疫苗,于30和90天再皮内注射0.1ml。对96例狂犬病马血清免疫球蛋白(ERIG)皮试阴性的患者,于第0天用ERIG(401U/kg)尽可
The authors used post-exposure prophylaxis with the purified Vero cell rabies vaccine (PVRV) according to the Thai Red Cross intradermal inoculation (TRC-ID) program to evaluate the efficacy of this regimen. 100 patients were selected according to the following criteria: (1) Rabbit animal bites confirmed by fluorescent antibody test; (2) Bite to start treatment no longer than 48 hours; (3) Bleeding due to skin lesions; (4) No corticosteroids or immunosuppressive agents, non-alcoholic or drug addicts, no chronic liver disease; (5) rabies vaccine has not previously been vaccinated. Each 0.5ml vaccine contains 3.17IU antigen. All patients received intradermal injection of 0.1 ml vaccine on both sides of the deltoid area on days 0, 3, and 7, and 0.1 ml intradermally on days 30 and 90. In 96 rabies horse serum immunoglobulin (ERIG) skin test-negative patients, on day 0 with ERIG (401U / kg) as much as possible